Concord Biotech Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Concord Biotech reported Q1 FY27 revenue of INR257 crores, up 26.2% year-on-year, driven by export growth of 46% and broad-based gains across immunosuppressants, anti-infectives, oncology and antifungal categories. EBITDA grew 34% to INR82 crores with margins of 32%, while PAT rose 31% to INR58 crores. Management attributed the growth to new product launches, wallet share gains from pricing advantages, and spillover of delayed customer procurement from the prior year.
Concord Biotech reported a revenue decline for Q4 FY26 and full year FY26, citing industry headwinds including US tariff-related procurement delays, CDSCO written confirmation approval issues affecting European supplies, Middle East geopolitical disruptions, and a stalled US Veterans Affairs tender. EBITDA margin for FY26 stood at around 35%, or approximately 39% excluding costs from the new injectable facility and the US subsidiary Stellon Biotech. Management said it expects growth in FY27 to be in line with or slightly better than its historical rate, supported by new customer acquisitions, CDMO opportunities, and normalization of deferred supplies.